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Abstract 
Purpose: We report the screening process and recruitment figures for the VISION trial: 
Visual Impairment in Stroke; Intervention Or Not. 
Methods: Prospective, randomised, single-blinded, three-arm controlled trial in fourteen 
UK acute hospital stroke units. Stroke teams identified stroke survivors suspected as 
having homonymous hemianopia. Interventions included Fresnel prisms versus visual 
search training versus standard care (information only). Primary outcome was change in 
visual field assessment from baseline to 26 weeks. Secondary measures included 
change in quality of life questionnaires.  
Results: Recruitment opened in May 2011. 1171 patients were screened by the local 
PIs. 178 of 1171 patients (15.2%) were eligible for recruitment: 87 patients (7.4%) 
provided consent and were recruited. 91 patients (7.8%) did not provide consent. 993 of 
1171 patients (84.8%) failed to meet the eligibility criteria.  Almost half were excluded 
due to complete/partial recovery of hemianopia (43.6%; n=511). 
Conclusions: The most common ineligibility reason was recovery of hemianopia. When 
designing future trials in this area, changes in eligibility criteria/outcome selection to 
allow more patients to be recruited should be considered, e.g. less stringent levels of 
visual acuity/refractive error. Alternative outcomes measurable in the home 
environment, rather than requiring hospital attendance for follow-up, could facilitate 
increased recruitment.  
 
Introduction 
Homonymous hemianopia is loss of half of the field of vision to the right or left side. It 
may be complete, in which total field loss occurs to one side from the vertical midline 
outwards, or may be partial, in which part of the field remains either centrally or in the 
periphery (temporal, superior or inferior remnant) [1].  
Homonymous hemianopia is a common sequela to stroke and is reported in up to 57% 
acutely post stroke onset [2-5]. If a patient recovers, this is usually by 3 months and 
may be full, with a return of normal visual fields in up to 44%, or partial recovery in up to 
72% [2,6-12]]. Where homonymous hemianopia persists it has considerable impact to 
daily life. Studies that have addressed this impact report a loss of confidence, increased 
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accidents and collisions, reading difficulties, navigation issues, loss of driving, and 
issues with isolation [2,13-15]. A variety of treatment options have been reported for 
homonymous hemianopia and these are summarised in a recent Cochrane systematic 
review [16]. However, there remains limited evidence for the efficacy of treatment 
options. Our pilot trial sought to compare two inexpensive treatment options (prism 
therapy and visual search training) with a control group of standard care [17]. This 
paper reports the VISION trial (Visual Impairment in Stroke; Intervention Or Not) 
screening data and final recruitment numbers. 
  
Methods 
The VISION trial was conducted as a multi-centre three arm pilot randomised controlled 
trial with independent assessment of results across 14 hospitals. For the full trial 
protocol please see reference 17. Interventions were: Fresnel prisms (arm a); visual 
search training (arm b) and standard care (information sheets only) (arm c). 
Setting 
The trial was undertaken in hospital in- and out-patient, and primary care rehabilitation 
settings.  
Target population 
Patients were identified in the acute phase following admission to hospital with a stroke 
(at 2 weeks post stroke onset).   
Inclusion criteria 
Participants were 18 years of age and older, and had best corrected visual acuity of 
≥6/18 in either eye, homonymous hemianopia and refractive error within ±5D. 
Measurements of vision were by orthoptic assessment. 
Exclusion criteria 
Participants were excluded if they were: unable to consent due to severe cognitive 
impairment; unwilling to participate in the study; had ocular motility impairment and 
visual inattention in addition to the visual field impairment (as assessed by the 
orthoptist); had pre-existent visual field impairment. 
Screening 
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The stroke team within participating stroke units identified stroke survivors suspected of 
having a homonymous hemianopia. The stroke research nurse listed details of these 
patients on the trial screening log. The Principal Investigator for the trial was an 
orthoptist specialising in the assessment of stroke-related visual impairment who 
arranged assessment of these patients  
Recruitment 
Patients listed on the trial screening log were contacted either in person if an in-patient, 
or via telephone if discharged. Patients were invited for eye assessment, conducted by 
the PI in the eye clinic. At assessment, patients who did not meet the inclusion criteria 
were excluded and reasons for exclusion were recorded. All patients meeting the 
inclusion criteria were invited to participate in the trial. Patients who declined to 
participate were invited to provide a reason, although PIs made it clear that this was not 
required; any reasons provided were recorded..  
 
Results 
Recruitment period 
The VISION trial opened to recruitment in May 2011. During the recruitment period 
fifteen NHS Trusts were opened to recruitment; five of these opened in the first months. 
Recruitment was slow and the number of recruiting sites was subsequently increased. 
The month and year when each site opened to recruitment is given in Table 1. Time 
taken to obtain Research and Development unit approvals locally combined with 
completion of trial setup paperwork by local research teams ranged from 1 to 21 
months. One site opened in the final month of recruitment period and therefore did not 
contribute to screening and so is not listed in the results tables. 
 
Screening data 
Total screening and recruitment numbers across 14 sites are provided in Table 1. A 
total of 1171 patients were identified by the stroke team as having suspected 
homonymous hemianopia and were recorded on the trial screening log. Figure 1 shows 
the flow of eligibility. 
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In total 993 patients (993/1171, 84.8%) failed to meet the eligibility criteria or could not 
be recruited to the trial for a variety of other Reasons; Table 2 provides a breakdown of 
these. The most common reason was failing to meet the criteria of a stable 
homonymous hemianopia (present no less than 2 weeks and no longer than 26 weeks 
post stroke) because of full or partial recovery in 511 patients (511/1171, 43.6%). 
Coexistent ocular motility impairment and/or presence of visual inattention was a failed 
criteria by 161 patients (161/1171, 13.7%) as was failure to achieve best corrected 
distance visual acuity of 0.5 logMAR or better in 97 patients (97/1171, 8.3%). Pre-
existent visual field loss ruled out recruitment of 46 patients (46/1171, 3.9%) and 117 
patients (117/1171, 10.0%) could not be recruited to the trial because they were unable 
to consent or could not understand the trial information because of cognitive or 
communication impairments.  
Recruitment data 
In total 178 patients (178/1171, 15.2%) were eligible for recruitment and 87 of these 
(87/178, 48.9%) provided consent and were subsequently recruited to the trial. Reasons 
eligible patients declined consent are outlined in Table 2. Ninety-one patients did not 
provide consent (91/178, 51.1%), of which 52 (52/91, 57.1%) did not disclose a reason. 
Of the patients who did provide a reason, twenty-five patients (25/91, 27.5%) did not 
want to attend the follow-up appointments required for the trial and eight (8/91, 8.8%) 
did not want to be randomly assigned.  
The overall proportion of screenings resulting in recruitment was 7.4% (87/1171). This 
proportion varied across the 14 sites from 1.26% (3/238) to 20% (5/25) with table 1 
providing more details. Time open to recruitment varied across sites with a median of 
17.5 months and range of 7 to 28 months (table 1) with lower recruitment rates in sites 
open longest. 
 
Discussion 
The recruitment phase of the VISION trial commenced in May 2011 and ceased in 
August 2013. During this period 1171 patients were screened of which less than 10% 
were randomised (n=87). Recruitment was initially slow and formal feedback from the 
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PIs during an end-of-trial investigator meeting suggests this may be due partly to lack of 
familiarity with the trial and research process.  
Research is relatively new in this field. Staff, who are new to research trials, must learn 
new processes (as was the case in our trial). For this trial a local orthoptist was the 
principal investigator at each recruitment site. Many of our PIs had participated in 
previous observation studies but this was their first PI role in a trial.  
There was also a learning curve for the stroke research nurses. Although experienced 
at recruiting, for many they had to acquire knowledge of the various visual conditions 
that could co-exist with homonymous hemianopia to aid identification of suspected 
hemianopia. Continuous feedback and information were provided by the orthoptists to 
the stroke teams to facilitate an on-going update of knowledge of visual conditions, 
particularly for new staff with no prior vision experience. It was recognised that lack of 
knowledge and information could be a limitation in the identification of hemianopia by 
members of the stroke team. Sites opening to recruitment a year or longer after the 
initial sites possibly benefitted from the knowledge and experience passed on by the 
orthoptist PIs of the original sites. Consequently recruitment rate was generally higher 
for the later opening sites. These may be important lessons for future studies in this 
area. 
Low recruitment numbers remained an issue through the first year of recruitment; there 
were fewer eligible patients than expected and smaller numbers of patients agreeing to 
take part. Slow and low numbers of recruitment to trials is well reported [18-21]. Barriers 
to trial participation include a lack of patient time, issues with their perceived importance 
of the trial, poor patient-clinician relationship and a lack of compatibility between the trial 
protocol and usual clinical practice [19]. Strategies to improve recruitment to trials have 
been advocated and include telephone reminders, participant opt-out versus opt-in 
options for trial contact and open designs [21].   
We found a high number of patients who did not meet the trial inclusion criteria due to 
full or partial recovery of hemianopia but other reasons included; death prior to baseline 
assessment, further stroke, patients moved out of area or could/did not attend baseline 
assessment appointments. Patients who were eligible but who did not wish to consent 
to the trial often did not want to attend follow-up appointments, did not want to be 
8 
 
randomly assigned to a treatment group or be assigned to the control (no treatment) 
group, wanted to wait for natural recovery, did not wish to travel to the hospital for 
appointments (a requirement for outcome measures), did not anticipate any benefit to 
participating in the trial or their family did not wish them to participate.  
Almost half (511/1171, 43.6%) of all screenings resulted in patients not being recruited 
for reasons related to recovery of hemianopia, which included either full recovery with 
return to normal visual field to the previously affected side, or partial recovery to less 
than one quadrant. The literature reports that up to 44% of individuals have full recovery 
of visual field and up to 72% have partial recovery although the extent of this recovery is 
not stated [2,6-12]. Our screening results show 43.6% full or partial recovery but of note, 
the partial recovery in our excluded cases was to less than a quadrant of visual field. 
This is a positive finding as a small visual field defect, particularly in the peripheral 
visual field, may not functionally impede an individual to anything near the extent of 
impact from complete homonymous hemianopia. This factor should be taken into 
consideration when planning future trials.  
Of total screenings, 161 patients were excluded (161/1171, 13.7%) who had acquired 
eye movement deficits that prevented accurate horizontal gaze to the side of the 
hemianopia, for example horizontal gaze palsy. The reason for this is that treatment 
with visual search strategies utilised eye scanning exercises. These rely on the patient 
being able to make eye movements to look at different targets to the right and left sides 
of the exercise card. It was important to exclude eye movement deficits that might 
impede the process of doing the eye scanning exercises. Thus we propose this 
inclusion criterion should remain in future trials using visual search training.  
Presence of high refractive error precluded the recruitment of only seven patients 
(7/1171, 0.6%). Formal quantitative perimetry of the peripheral visual field is typically 
done without glasses as the frames can impede the test by blocking the stimuli. 
Individuals with high refractive errors may therefore not detect stimuli if undertaking the 
test without their glasses. Thus they were excluded. The level of visual acuity was set at 
0.5 logMAR or better level, as quantitative perimetry requires sufficient visual acuity to 
maintain adequate fixation of the central stable target during formal assessment. Ninety-
seven patients (97/1171, 8.3%) did not meet this criterion. It is possible to increase the 
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visual acuity cut-off to a lower acuity level but not less than 6/60 Snellen or 1.0 logMAR 
level and future trials could consider this. This change in the inclusion criteria would 
allow a small increase in recruitment of patients but it would still be necessary to 
exclude those with visual acuity worse than 6/60 or 1.0 if formal perimetry remained an 
outcome measure.  
A further consideration in relation to formal visual field assessment is that a number of 
patients could not participate because they did not wish to attend follow-up 
appointments or had transport difficulties so could not travel for appointments (35 
patients, 3%). We required hospital attendance for follow-up appointments because 
formal visual field assessment was an outcome measurement. A consideration for 
future hemianopia trials is whether formal visual field perimetry is required as an 
outcome measure. If outcome measurements could be completed at home or 
community settings, recruitment may be improved. Furthermore, exclusion based on 
refractive error or level of visual acuity may not be necessary.  
 
Conclusions 
Of 1171 patients screened with possible hemianopia, we identified 178 eligible patients 
(15.2%) from which we recruited 87 patients, which represents 7.4% of the total 
screened patients and 48.9% of eligible patients. Just under half of patients screened 
could not be recruited because their hemianopia had fully or partially recovered which is 
a positive finding for stroke outcomes. It would be possible to recruit a small additional 
number of hemianopia patients with less stringent inclusion criteria for level of visual 
acuity and refractive error, and with varied outcome measurements not requiring formal 
hospital visits for perimetry or other quantitative assessments. Support for staff when 
screening and recruiting to trials, may promote improved recruitment rates across multi-
centre trials. Consequently although we recruited fewer participants than we anticipated, 
our findings are important for the future planning of trials and studies for the care and 
treatment of patients with homonymous hemianopia.  
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Table 1  Summary of site screening and recruitment 
Sit
e 
Date site opened to 
recruitment 
Months open to 
recruitment* 
Number 
screened 
patients 
Number 
ineligible 
patients 
Number 
unwilling 
patients 
Number 
eligible 
patients 
Total patients 
recruited Consent 
1 May 2011 28 122 110 5 12 7 58% 
2 May 2011 28 104 92 3 12 9 75% 
3 May 2011 28 187 158 15 29 14 48% 
4 May 2011 28 112 85 13 27 14 52% 
5 August 2011 25 238 224 11 14 3 21% 
6 March 2012 18 72 64 5 8 3 38% 
7 March 2012 18 38 33 3 5 2 40% 
8 April 2012 17 36 18 11 18 7 39% 
9 April 2012 17 89 77 9 12 3 25% 
10 May 2012 16 53 42 5 11 6 55% 
11 June 2012 15 25 13 7 12 5 42% 
12 November 2012 10 31 23 2 8 6 75% 
13 January 2013 8 22 18 2 4 2 50% 
14 February 2013 7 42 36 0 6 6 100% 
15 July 2013 2 NA NA NA NA NA . 
*Rounded up to nearest month 
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Table 2 Reasons for being ineligible for recruitment and not providing consent 
Reason: ineligible Total 
screenings 
Proportion Reason: consent not provided Total 
number   
Proportion  
Unstable hemianopia 511 43.6% Did not wish to provide reason 52 57.1% 
Ocular motility impairment and/or 
visual inattention  
161 13.7% Did not want to attend follow up visits 25 27.5% 
Not able to consent / understand  117 10.0% Did not want to be randomly assigned 
treatment 
8 8.8% 
Visual acuity worse than 0.5 
logMAR 
97 8.3% Did not want to be assigned to information 
only group 
1 1.1% 
Pre-existent visual field impairment  46 3.9% Other reason: Terminal patient 1 1.1% 
Died 33 2.8% Other reason: Patient wishes to see if 
recovers before participating 
1 1.1% 
Moved/lived out of area 17 1.5% Other reason: Family did not want to 
participate 
1 1.1% 
Could not attend 22 1.9% Other reason: Patient wishes to have more 
time to decide 
1 1.1% 
Did not attend  11 0.9% Other reason: Patient does not see benefit in 
trial 
1 1.1% 
Unable to contact patient  11 0.9% Other reason: Patient does not want to travel 
to appointments 
1 1.1% 
Further stroke 8 0.7% Total patients 91 100% 
High refractive error  7 0.6% 
Unable to read and understand 
English 
3 0.3% 
Further TIA (transient ischaemic 
attack) 
2 0.2% 
Does not have transport 2 0.2% 
Not 18 years of age or older  2 0.2% 
Other:  5 0.5% 
 No reason provided 2 0.2% 
Total patients 993 84.8% 
Other = Patient denied vision problem, Barrier nurse, Unable to be assessed by orthoptist, Patient having further treatment for migraine. 
 
